Considering the unsatisfactory results of treatments targeting the ECM in pancreatic cancer, the role of KLHL32 in shaping the ECM and its value for drug development warrant more mechanistic and preclinical studies. This evidence concerns the gene KLHL32 and familial pancreatic carcinoma.